Brain metastases in ALK-positive NSCLC – time to adjust current treatment algorithms

Frank Griesinger¹, Julia Roeper¹, Christoph Pöttgen², Kay C. Willborn³ and Wilfried E.E. Eberhardt⁴

¹Department of Hematology and Oncology, University Department Internal Medicine-Oncology, Pius-Hospital, Medical Campus University of Oldenburg, Oldenburg, Germany
²Department of Radiotherapy, University Hospital Essen, Essen, Germany
³Department of Radiotherapy and Radiooncology, University Department of Medical Physics, Pius-Hospital Oldenburg, University of Oldenburg, Oldenburg, Germany
⁴Department of Medical Oncology, West German Cancer Center, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany

Correspondence to: Frank Griesinger, email: Frank.Griesinger@Pius-Hospital.de

Keywords: non-small cell lung cancer; ALK-positive; brain metastases; ALK-inhibitors

Received: January 18, 2018  Accepted: August 05, 2018  Published: October 12, 2018

Copyright: Griesinger et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The progress in molecular biology has revolutionized systemic treatment of advanced non-small-cell lung cancer (NSCLC) from conventional chemotherapy to a treatment stratified by histology and genetic aberrations. Tumors harboring a translocation of the anaplastic-lymphoma-kinase (ALK) gene constitute a distinct genetic and clinico-pathologic NSCLC subtype with patients with ALK-positive disease being at a higher risk for developing brain metastases. Due to the introduction of effective targeted therapy with ALK-inhibitors, today, patients with advanced ALK-positive NSCLC achieve high overall response rates and remain progression-free for long time intervals. Moreover, ALK-inhibitors seem to exhibit efficacy in the treatment of brain metastases. In the light of this, it needs to be discussed how treatment algorithms for managing patients with brain metastases should be modified. By integrating systemic ALK-inhibitor therapy, radiotherapy, in particular whole brain radiotherapy might be postponed deferring potential long-term impairment by neurocognitive deficits to a later time point in the course of the disease. An early treatment of asymptomatic brain metastases might offer patients a longer time without impairment of cerebral symptoms or radiotherapeutic interventions. Based on an updated extensive review of the literature this article provides an overview on the epidemiology and the treatment of patients’ brain metastases. It describes the specifics of ALK-positive disease and proposes an algorithm for the treatment of patients with advanced ALK-positive NSCLC and brain metastases.

INTRODUCTION

Lung cancer remains one of the major challenges in oncology. It is the most frequent cause of cancer death worldwide [1, 2, 3]. In Germany, it is the second most frequent newly diagnosed malignant disease in men after prostate cancer, and the third most frequent in women after breast and colon cancer. In 2012, according to the most recent numbers of the Robert-Koch-Institute, 34,490 men and 18,030 women were diagnosed in Germany. Lung cancer was the leading cause of cancer death in men with 29,713 deaths (25%) and the second most frequent cause of cancer death in women with 14,752 deaths (15%). Five-year overall survival rates were 16% for men and 21% for women [4]. According to the American Cancer Society non-small-cell lung cancer (NSCLC) is the most common type and accounts for about 85% of all lung cancers. Squamous-cell carcinoma (25-30%),
adenocarcinoma (40%) and large-cell carcinoma (10-15%) all are subtypes of NCSLC [82].

Treatment of patients with non-small-cell lung cancer (NSCLC) is guided by disease stage. Early stages and some of the locally advanced stages are treated with a curative intent. Surgery, radiation, primary (neoadjuvant) and adjuvant chemotherapy are the respective treatment options, mostly as one component of combined multimodality therapy [5, 6]. Treating patients with stage IV disease represents a palliative setting in which improvement of symptoms, retaining or even improving quality of life and prolonging overall survival are relevant treatment objectives [5, 6]. Oligometastatic disease (OMD) may represent a potentially curative situation as long as there is only a limited involvement of mediastinal lymph nodes [83].

Over the last 15 years medical research and, in particular, the progress in molecular biology has fundamentally changed our understanding of lung cancer. Meanwhile we know that the genotype of the tumor is an important prognostic and in some cases predictive factor besides the classical clinico-pathologic factors such as disease stage, histology, gender, performance status or comorbidity. Moreover, the progress in molecular biology revolutionized systemic treatment of advanced NSCLC from chemotherapy to a treatment stratified by histology and genetic aberrations consisting of monoclonal antibodies, a panel of targeted kinase-inhibitors and chemotherapy [5, 6]. All NSCLC patients with a non-squamous histology and never or light smokers (< 10 pack years and > 15 years from smoking cessation) with squamous-cell carcinoma should be screened for EGFR mutations and for ALK- and ROS1 translocations before starting a systemic first-line therapy [6, 54].

ALK-positive NSCLC

Tumors harboring a translocation of the anaplastic-lymphoma-kinase (ALK) gene constitute a distinct genetic and clinico-pathologic NSCLC subtype. An inversion on the short arm of chromosome 2 results in a fusion of the ALK-gene with the "echinoderma microtubule-associated protein-like 4" (EML4)-gene. Transcription of this newly formed oncogene results in the production of the fusion protein EML4-ALK. By activation of subsequent signal transduction cascades, the fusion protein leads to cell proliferation, inhibition of apoptosis and ultimately to the stimulation of tumor growth. This particular genetic NSCLC subtype was initially described by Soda and colleagues [7]. Since then, a number of EML4-ALK-variants [8, 9, 7, 10, 11, 12] and ALK fusion proteins with alternative fusion partners other than EML4 have been discovered [11, 13]. An ALK-translocation is detected in 3-7% of all NSCLC patients [7, 9, 14, 15, 10, 12, 16]. Their tumors rarely exhibit simultaneous mutations of EGFR or KRAS [17], in contrast to EGFR mutations, ALK translocations do not seem to be dependent on ethnicity.

ALK-positive NSCLC is not only a genetic subtype but also a clinical entity, ie patients having this tumors do carry specific clinical characteristics. ALK-positive tumors are mainly, but not exclusively associated with adenocarcinoma histology. Patients with ALK-positive NSCLC more commonly are never- or light smokers, and they have a median age of between 50 and 55 years, which is about 10 to 15 years lower than for the general NSCLC population and also the EGFR mutated patients [9, 13, 18, 19, 20, 21, 22, 23, 84].

While mutations of the EGFR gene represent a prognostic and a predictive marker, an ALK translocation is mainly a predictive marker, as the prognosis of patients not treated with ALK-specific tyrosine kinase inhibitors (TKI) is as unfavorable as the prognosis of NSCLC patients with no detectable EGFR or ALK gene mutation (wild-type (WT) NSCLC). Inhibition of the ALK tyrosine kinase and its subsequent signal transduction pathway with specific TKI’s results in tumor growth arrest, improved clinical response and a survival benefit in ALK-positive NSCLC as compared to WT NSCLC [24, 25, 26, 27, 28].

Brain metastases

Brain metastases are a relevant problem in NSCLC. Up to 64% of all patients with lung cancer develop brain metastases during the course of the disease [5, 29]. Numbers for the incidence of brain metastases in NSCLC are available from big patient populations. The incidence was 23.2% in a retrospective study with 1.127 consecutive patients [30]. 17% of 5.133 NSCLC patients documented in a US tumor registry were diagnosed with brain metastases during the course of their disease [31]. A retrospective study with 482 consecutive stage IIIB/IV NSCLC patients reported an incidence of <36% over the course of the disease [32]. A retrospective evaluation of 975 consecutive stage I-II NSCLC patients with curatively intended surgery found the 5-year risk for metastasizing to the brain to be as high as 10% [33]. In the prospective German registry CRISP including all-comers NSCLC receiving systemic therapy, the incidence of brain metastases is 18% (unpublished data, Griesinger et al).

Age < 60 years and adenocarcinoma histology are risk factors for developing brain metastases [34, 35, 33, 36, 37, 38]. According to a retrospective study in 629 patients, the incidence of brain metastases for NSCLC patients with adenocarcinoma amounted to 26.9% [39]. Another retrospective study in 234 NSCLC patients with adenocarcinoma reported an incidence of 32.5% [40]. A cohort study from Israel found 23 of 252 patients with metastatic NSCLC to be ALK-positive. The cumulative incidence of brain metastasis was 23.8% initially and 23.8%, 45.5% and 58.4% after 1, 2 and 3 years, respectively [41]. This indicates, that the longer the patients live the more likely they will develop brain metastases. According to Johung et al. 30% of an ALK-pos. NSCLC collective had brain metastases at the time of
diagnosis. All other patients developed brain metastases with a median time of 27 months (range: 2-174) since first diagnosis [64]. Table 1 summarizes landmark data on the development of brain metastases in stage IIIB/IV NSCLC patients.

Patients with ALK-positive NSCLC seem to be at higher risk for developing brain metastases [42, 43]. However, epidemiologic data are still rare. The analysis of three databases comprising a total of 1,352,449 lung cancer patients from US routine clinical practice found 947 patients with ALK-positive disease. Of these, 28% had brain metastases diagnosed with a median of 88 days after primary diagnosis [44]. There are also numbers from clinical trials which can, however, only serve as rough estimates due to the selected patient populations treated within clinical trials. In the phase-III study PROFILE 1014 that compared crizotinib as first-line therapy against chemotherapy, 27% of patients had brain metastases at baseline [45]. 40% of patients in the phase-III study ALEX comparing alecinitib vs. crizotinib as first-line therapy showed brain metastases at baseline [86]. In the phase-III Study ASCEND 4 comparing in first line ceritinib vs. chemotherapy (pemetrexed and cis- or carbolplatin) in ALK+ NSCLC, 32% of patients had brain metastases at diagnosis. Although these different studies had different inclusion criteria (treated brain metastases only in the crizotinib trial, asymptomatic metastases with or without irradiation in the ceritinib and alecinitib trials), the rates of CNS metastases at diagnosis were comparable. In the second line setting, the PROFILE 1007 study assessing crizotinib versus chemotherapy after prior platinum (ALK-inhibitor naïve patients), the proportion of patients with brain metastases was 35% [24]. In the phase-I study ASCEND-1, in which ALK-inhibitor naïve and ALK-inhibitor pretreated patients received ceritinib, 31% of ALK-inhibitor naïve and 60% of ALK-inhibitor pretreated patients had brain metastases [47]. In the phase-II study ASCEND-3 ALK-inhibitor naïve patients with up to 3 prior lines of chemotherapy received ceritinib, 39.5% of whom had brain metastases at inclusion in the study [48]. In the phase-II study ASCEND-2, 71.4% of patients progressing during or after crizotinib had brain metastases [49]. In the phase-III study ASCEND-5 comparing chemotherapy vs. ceritinib in crizotinib-pretreated patients, 60% and 57% had brain metastases at baseline [50]. In the randomized phase-II trial ALTA comparing two doses of brigatinib in crizotinib-resistant patients, 69% had brain metastases at baseline [51]. The proportion of patients with brain metastases in both phase-II trials testing alecinitib after prior crizotinib was 60% at baseline [28, 26].

A number of factors contribute to the detection of brain metastases among them disease stage, subtype, tumor biology and prior therapies but also the diagnostic methods and intervals [5, 52]. A retrospective study with 1,602 NSCLC patients treated between 2000 and 2013 reported a median time of 259 days (8.5 months) from primary diagnosis to the onset of brain metastases. It was not specified whether the metastases had been diagnosed by imaging diagnostics or due to the emergence of symptoms [53]. Another study found a median time of 14.3 months for the onset of brain metastases in NSCLC patients with adenocarcinoma when they were diagnosed clinically [39].

Currently, screening for brain metastases is not recommended as a routine follow-up measure for asymptomatic patients [5, 54]. The extensive literature search performed as the basis for this review article did not retrieve data documenting at which point in time NSCLC patients and, in particular, patients with ALK-positive NSCLC with initially asymptomatic brain metastases become symptomatic. It is, however, only a question of time until brain metastases grow to a critical size. The size of brain metastases from NSCLC of 19 minimally symptomatic patients was documented by serial magnetic resonance imaging (MRI) during and after first-line chemotherapy. Tumor volume increased on average by 1.7% per day and doubled after a median of 58.5 days [55].

Patients with brain metastases are compromised by headaches, signs of increased intracranial pressure, focal neurological signs (hemiparesis, aphasia, ataxia, vision disorders or brain stem symptoms), epileptic seizures or neurocognitive deficits [5, 56, 57, 58]. Impairments of neurocognitive function depend on the size and location of the brain lesions and the surrounding perifocal edema. A study of 401 patients with whole brain radiotherapy (WBRT) including 251 NSCLC patients found 21-63% to have some kind of impaired neurocognitive function at baseline. Patients progressing 2 months after WBRT had a deterioration of neurocognitive function compared to baseline. The study found an improvement in two domains of neurocognitive function if imaging showed a partial response 2 months after WBRT [58].

Studies documenting the follow-up of curatively resected NSCLC patients show that those with asymptomatic recurrences have a survival benefit compared to patients with symptomatic recurrences [59, 60]. It is, however, unclear whether being symptomatic or not does influence the prognosis of patients with brain metastases. A retrospective study documented symptoms in 46.7% of patients with brain metastases from lung cancer. Overall brain metastases were detected in 31.3% (n=61) of patients by MRI which was an obligatory staging measure. No differences in size and localization of metastases, presence of perifocal edema, hemorrhage or necrosis were noticed between neurologically symptomatic and asymptomatic patients. Also, tumor load in asymptomatic patients was comparable to that of patients with symptomatic brain metastases [61]. Another series of 183 newly diagnosed NSCLC patients who had MRI screening did not find differences in overall
survival (OS) or 1-year survival between patients with symptomatic (n=7) and asymptomatic (n=38) brain metastases [52]. A further retrospective, monocentric study compared neurologically asymptomatic (n=12) and symptomatic NSCLC (n=69) patients with brain metastases and found longer OS for the asymptomatic group (median OS 7.5 vs. 4 months). A higher rate of patients from the asymptomatic group did not develop any neurologic signs in the further course of therapy. They identified an active treatment i.e. surgery, chemotherapy and/or radiotherapy as the strongest prognostic factor and concluded that patients benefit from early treatment of brain metastases [62].

Overall prognosis of NSCLC patients with central nervous system (CNS) metastases is poor. A study with 1,833 patients reported a median OS of 7 months [63]. Patients with ALK-positive NSCLC and brain metastases may have a more favorable prognosis presumably due to treatment with ALK-inhibitors. This is suggested by a retrospective study in 90 ALK-positive NSCLC patients treated between 2007 and 2014 in 6 US centers. About 30% of patients had brain metastases already at primary diagnosis, 80% were younger than 60 years, 47% had more than 3 metastases, 83% were stage IIIB or IV, 70% had additional extracranial metastases. Median OS after the onset of brain metastases was 49.5 months and median PFS 11.9 months in this group of patients characterized by rather unfavorable prognostic factors. 84 patients had been treated with crizotinib, 41 with ceritinib. Repeated radiotherapy interventions were common. 45% of patients

Table 1: Landmark data on the development of brain metastases for patients with stage IIIB/IV

| Author                  | Population                              | Landmark data for brain metastases (BM)                                      |
|-------------------------|-----------------------------------------|--------------------------------------------------------------------------------|
| Alsan Cetin I et al.    | NSCLC Stage IIIA/IIIB                   | Incidence of BM after 2 years 23%                                             |
| 2013 [78]               | N=200                                   |                                                                               |
| Gaspar LE et al.        | NSCLC Stage IIIA/B and chemotherapy     | Onset of BM 22.5% during therapy, 24% 0-16 weeks after therapy, 14% 16 weeks - 6 months after therapy, 22.5% 6-12 months after therapy, 17% > 12 months after therapy |
| 2005 [36]               | N=421                                   |                                                                               |
| N=71 with BM            |                                         |                                                                               |
| Boggs DH et al.         | NSCLC Stage IIIA, IIIB, IV without BM   | Incidence of BM after 1 year 13% without and 18% with temozolomide           |
| 2014 [79]               | and no PD                               |                                                                               |
|                        | N=45                                    |                                                                               |
| Liu J et al.            | Wt NSCLC Stage III/IV without BM        | Median time to onset of BM 19.0 months                                        |
| ASCO 2013 [94]          | N=72                                    | Incidence after 1 year 21.1%, after 2 years 50.2%                             |
| Hsiao et al.            | NSCLC Stage IIIB/IV                     | Incidence of BM 42% after 3 months, 54% after 1 year, 64% after 2 years      |
| 2013 [32]               | N=482                                   |                                                                               |
| Arrieta O et al.        | NSCLC Stage IIIB/IV                     | Incidence of BM 27% after 1 year, 32% after 2 years                          |
| 2009 [80]               | N=293                                   | Incidence of BM in patients with adenocarcinoma 16.4% after 1 year, 20.2% after 2 years |
| Hendriks LE et al.      | Wt NSCLC Stage IV                       | Mean time to onset of BM 10.7 months                                          |
| 2014 [81]               | N=62                                    |                                                                               |
| Rangachari D et al.     | ALK-pos. NSCLC                          | Cumulative incidence of BM 23.8% bei Erstdiagnose, 23.8% after 1 year, 45.5% after 2 years, 58.4% after 3 years |
| 2015 [41]               | 91.3% Stage IV                          |                                                                               |
| Chua D et al.           | NSCLC and ≥ 1 BM                        | Median time to CNS progression 3.1 months with WBI + temozolomide and 3.8 months with WBI |
| 2010 [69]               | N=47 with WBRT + temozolomide          |                                                                               |
| N= 48 with WBI          |                                         |                                                                               |
| Han G et al.            | NSCLC without BM at primary diagnosis   | Cumulative incidence of BM 4.2% after 1 year, 18.7% after 2 years for wt NSCLC |
| ASTRO 2015 [40]         | N=195                                   |                                                                               |
| Duma N et al.           | NSCLC                                  | Median time from primary diagnosis to onset of BM 259 days                    |
| ASCO 2015 [53]          | N=172                                   |                                                                               |

*Data on EGFR-positive NSCLC or EGFR-inhibitor treated patients were not incorporated.
had progressive brain metastases at the time of their death [64].

Treatment of brain metastases

Treatment of brain metastases depends on the number of lesions, location and on the patient's performance status and mostly involves radiotherapy. In case of a solitary lesion, local treatment by surgical resection or stereotactic radiotherapy may suffice and whole brain radiotherapy (WBRT) may be postponed until recurrence or progression. A similar strategy can be followed for patients in a good performance status with 2-4 brain metastases. In that situation postponement of WBRT may only be an option for individual patients in order to prevent radiotherapy associated side effects. However, one should keep in mind that while adjuvant WBRT has an effect on local tumor control, it has no proven impact on overall survival [54, 65, 66]. WBRT is the treatment of choice for multiple brain lesions [5]. Roughly 40% of patients respond [67, 58]. Median times for overall survival and time to CNS progression are about 4 months and 3 months, respectively [68]. In case of a very poor performance status and an unfavorable prognosis treatment may be limited to symptomatic steroid therapy.

Data from a current phase-III trial in 538 NSCLC patients and inoperable brain metastases showed no benefit for WBRT over supportive therapy with dexamethasone only. There was no significant difference in quality of life between the two treatment arms [69].

Systemic treatment with drugs crossing the blood-brain barrier is recommended for patients with asymptomatic or only minor symptomatic brain metastases. For those patients, radiotherapy is not generally indicated upfront but represents a therapeutic option in case of further progress [54].

Radiotherapy is associated with short- and long-term side effects. It may lead to acute exacerbation of peritumoral edema resulting in a transient, yet further deterioration of neurologic symptoms. Radiation-induced necrosis, encephalopathy, vascular damages or demyelination may occur 6 months after WBRT, in many cases irreversible and progressive. They may constitute solely radiographic findings or can result in neurocognitive impairment [56]. There is evidence that WBRT is associated with an increased risk of long-term deterioration of neurocognitive functions [70, 71]. This has been demonstrated by a study in which patients with a maximum of 3 CNS metastases with a diameter not exceeding 3 cm either received stereotactic therapy alone or in combination with WBRT. Survivors that had been treated with WBRT showed a worsening of neurocognitive functions [71]. Data from an RTOG-study suggest that WBRT sparing the hippocampal region may result in fewer neurocognitive deficits [72].

ALK-inhibitor therapy

The situation of patients with ALK-positive NSCLC has changed dramatically since the introduction of effective targeted therapy with ALK-inhibitors. Today, patients with advanced ALK-positive NSCLC achieve high overall response rates and remain progression-free for long time intervals. After prior platinum therapy, crizotinib resulted in ORR of 65%, median PFS of 7.7 months and median OS of 21.7 months [26]. First-line therapy with crizotinib achieved ORR of 74% and a median PFS of 10.9 months [45]. A phase-I study of ceritinib in 163 patients with advanced NSCLC and prior crizotinib showed an ORR of 56%, median duration of response of 8.3 months and median PFS of 6.9 months. In those 83 patients without prior ALK-inhibitor treatment, ORR was 72%, median duration of response 17 months and median PFS 18.4 months, respectively [25, 47]. These data were confirmed by the first-line study with ceritinib (ASCEND-4) which showed a significantly different ORR, PFS and DCR in ALK+ tumors in comparison with chemotherapy (HR for PFS: 0.55, 95% CI 0.42-0.73) [87]. In the phase-II study ASCEND-3, the ORR with ceritinib was 63.7% and median PFS 18.4 months in 124 ALK-inhibitor-naive patients with up to 3 prior lines of chemotherapy [48]. The phase-III ASCEND-5 in 231 crizotinib-pretreated patients compared chemotherapy vs. ceritinib and found a median PFS of 1.6 vs. 5.4 months (HR 0.49) and ORR of 7% vs. 39% [50].

A randomized phase-II study comparing two doses of brigatinib (90 mg qd and 180 mg qd) in 222 crizotinib-resistant patients reported ORR of 45% and 54% and median PFS of 9.2 months and 12.9 months, respectively [51].

A recent Japanese phase-III study in ALK-inhibitor naïve patients showed an ORR of 78.9% for crizotinib and 91.6% for alectinib. First-line treatment with alectinib resulted in a significant PFS benefit (ASCEND-4) which showed a significantly different ORR, PFS and DCR in ALK+ tumors in comparison with chemotherapy (HR for PFS: 0.55, 95% CI 0.42-0.73) [87]. In the phase-II study ASCEND-3, the ORR with ceritinib was 63.7% and median PFS 18.4 months in 124 ALK-inhibitor-naive patients with up to 3 prior lines of chemotherapy [48]. The phase-III ASCEND-5 in 231 crizotinib-pretreated patients compared chemotherapy vs. ceritinib and found a median PFS of 1.6 vs. 5.4 months (HR 0.49) and ORR of 7% vs. 39% [50].

A randomized phase-II study comparing two doses of brigatinib (90 mg qd and 180 mg qd) in 222 crizotinib-resistant patients reported ORR of 45% and 54% and median PFS of 9.2 months and 12.9 months, respectively [51].

A recent Japanese phase-III study in ALK-inhibitor naïve patients showed an ORR of 78.9% for crizotinib and 91.6% for alectinib. First-line treatment with alectinib resulted in a significant PFS benefit (ASCEND-4) which showed a significantly different ORR, PFS and DCR in ALK+ tumors in comparison with chemotherapy (HR for PFS: 0.55, 95% CI 0.42-0.73) [87]. In the phase-II study ASCEND-3, the ORR with ceritinib was 63.7% and median PFS 18.4 months in 124 ALK-inhibitor-naive patients with up to 3 prior lines of chemotherapy [48]. The phase-III ASCEND-5 in 231 crizotinib-pretreated patients compared chemotherapy vs. ceritinib and found a median PFS of 1.6 vs. 5.4 months (HR 0.49) and ORR of 7% vs. 39% [50].

A randomized phase-II study comparing two doses of brigatinib (90 mg qd and 180 mg qd) in 222 crizotinib-resistant patients reported ORR of 45% and 54% and median PFS of 9.2 months and 12.9 months, respectively [51].

A recent Japanese phase-III study in ALK-inhibitor naïve patients showed an ORR of 78.9% for crizotinib and 91.6% for alectinib. First-line treatment with alectinib resulted in a significant PFS benefit (ASCEND-4) which showed a significantly different ORR, PFS and DCR in ALK+ tumors in comparison with chemotherapy (HR for PFS: 0.55, 95% CI 0.42-0.73) [87]. In the phase-II study ASCEND-3, the ORR with ceritinib was 63.7% and median PFS 18.4 months in 124 ALK-inhibitor-naive patients with up to 3 prior lines of chemotherapy [48]. The phase-III ASCEND-5 in 231 crizotinib-pretreated patients compared chemotherapy vs. ceritinib and found a median PFS of 1.6 vs. 5.4 months (HR 0.49) and ORR of 7% vs. 39% [50].

A randomized phase-II study comparing two doses of brigatinib (90 mg qd and 180 mg qd) in 222 crizotinib-resistant patients reported ORR of 45% and 54% and median PFS of 9.2 months and 12.9 months, respectively [51].

A recent Japanese phase-III study in ALK-inhibitor naïve patients showed an ORR of 78.9% for crizotinib and 91.6% for alectinib. First-line treatment with alectinib resulted in a significant PFS benefit (ASCEND-4) which showed a significantly different ORR, PFS and DCR in ALK+ tumors in comparison with chemotherapy (HR for PFS: 0.55, 95% CI 0.42-0.73) [87]. In the phase-II study ASCEND-3, the ORR with ceritinib was 63.7% and median PFS 18.4 months in 124 ALK-inhibitor-naive patients with up to 3 prior lines of chemotherapy [48]. The phase-III ASCEND-5 in 231 crizotinib-pretreated patients compared chemotherapy vs. ceritinib and found a median PFS of 1.6 vs. 5.4 months (HR 0.49) and ORR of 7% vs. 39% [50].

A recent Japanese phase-III study in ALK-inhibitor naïve patients showed an ORR of 78.9% for crizotinib and 91.6% for alectinib. First-line treatment with alectinib resulted in a significant PFS benefit (ASCEND-4) which showed a significantly different ORR, PFS and DCR in ALK+ tumors in comparison with chemotherapy (HR for PFS: 0.55, 95% CI 0.42-0.73) [87]. In the phase-II study ASCEND-3, the ORR with ceritinib was 63.7% and median PFS 18.4 months in 124 ALK-inhibitor-naive patients with up to 3 prior lines of chemotherapy [48]. The phase-III ASCEND-5 in 231 crizotinib-pretreated patients compared chemotherapy vs. ceritinib and found a median PFS of 1.6 vs. 5.4 months (HR 0.49) and ORR of 7% vs. 39% [50].
is not actively eliminated from CNS tissue by efflux-mechanisms either. That is supported by preclinical data in mouse models with EML4-ALK-positive NSCLC showing a high brain-to-plasma ratio of alectinib [73] and by a phase-I study that detected relevant concentrations of alectinib in the cerebrospinal fluid of patients with brain metastases [74]. The first-line crizotinib study PROFILE 1014 allowed inclusion of patients with brain metastases if they had been treated and were neurologically stable without corticosteroid medication. Rate of intracranial disease control (stable disease, partial and complete response) in 39 patients with brain metastases was 85% after 12 weeks, 56% after 24 weeks and median time to intracranial disease progression was 15.7 months [27]. After prior platinum treatment, the intracranial disease control rate was 52% in patients with asymptomatic pre-irradiated brain metastases and 56% in patients without prior radiotherapy 12 weeks after crizotinib. The median time to intracranial tumor progression was 13.3 months and 7.0 months, respectively [75]. A retrospective analysis of 94 patients with brain metastases treated with ceritinib in the multicenter phase-I study ASCEND-1 found a median time to intracranial response of 6.1 weeks. The rate of intracranial disease control was 79% in ALK-inhibitor naïve patients and 61% in those pretreated with ALK-inhibitors. There was no difference in intracranial response in patients with or without prior radiotherapy [47]. In the phase-II study ASCEND-2 including patients progressing during or after crizotinib, intracranial response rate for 20 patients with active brain metastases (newly diagnosed or progressive) was 45% and the rate of intracranial disease control 80% [49]. ASCEND-3 reported rates of 61% for intracranial response and 76.9% for intracranial disease control. Systemic response in patients with brain metastases was poorer than in those without with an ORR of 57.1% and a median PFS of 10.8 months [48]. Chemotherapy and crizotinib pre-treated patients with brain metastases at baseline in ASCEND -5 had a median PFS of 4.4 months (3.5 - 6.2) versus 1.5 months (1.3 – 1.8) in the chemotherapy comparator group [HR 0.54 (95% CI 0.36 – 0.80)] [88]. The intracranial clinical benefit rate in patients with measurable brain metastases in the first-line trial ASCEND-4 for ceritinib at ≥12 weeks as well as ≥24 weeks was 86.4% (95% CI, 65.1-97.1) compared with 68.2% (95%CI, 45.1 – 86.1) and 50% (95%CI, 28.2-71.8) for chemotherapy respectively [87]. The randomized phase-II study comparing two doses of brigatinib (90 mg qd and 180 mg qd) reported rates for intracranial response of 36% and 67% and for intracranial disease control of 88% and 83%, respectively, in crizotinib-resistant patients with active brain metastases-[51]. Independent review committee-assessed intracranial ORR in patients with measurable brain metastases at baseline was 42% (11 of 26 patients) for the 90 mg qd-dosing and 67% (12 of 18 patients) for the 180mg qd-dosing. The median intracranial PFS was 15.6 months (95% CI, 7.3 to 15.7) and 12.8 months (95%CI, 11.0 to not reached) in the 90 mg and the 180mg dose, respectively [89]. Treatment of 84 crizotinib-resistant patients with brain metastases with alectinib resulted in a rate of intracranial disease control of 84.5% with 31% of all patients actually achieving a complete response. Median duration of CNS-response was 11.2 months [91]. Another phase-II study of alectinib in crizotinib-pretreated patients showed a disease control rate of 89% and complete response rate of 63% in all and 56% in radiotherapy-naive patients. The median duration of response was 11.1 months [26]. A pooled analysis of these two phase-II trials with alectinib found a lower risk of CNS progression if patients had no brain metastases before starting treatment with alectinib compared to those with a diagnosis of brain metastases at baseline. The radiotherapy-naive patients of the latter group had a lower probability of CNS progression [76]. In the ALUR trial, 107 patients were randomized to receive alectinib (n = 72) or 2nd line chemotherapy (pemetrexed or docetaxel, n=35) after failure of one platinum doublet chemotherapy and crizotinib. The primary study endpoint of PFS was reached with a HR of 0.15 by investigator assessment. The CNS response rate of patients with measurable brain metastases treated with alectinib was 54.2% and with chemotherapy it was 0% [92]. Within the multinational phase-III study ALEX the rates of CNS response in first-line patients with ALK-positive NSCLC and measurable CNS lesions at baseline for crizotinib were 50% (95% CI 28-72) compared to a CNS response rate of 81% (95% CI 58-95) with alectinib, resulting in a cause-specific hazard ratio of 0.16 (95%CI 0.10-0.28). The median duration of CNS response was 5.5 months (2.1-17.3) with crizotinib and 17.3 months (95%CI: 14.8 to not estimable) with alectinib. 29 patients (45%) of the alectinib group showed a complete CNS response, as compared to 5 patients (9%) in the crizotinib comparator group [86]. Furthermore, the cause specific HR for time to progression in the brain in pts with brain mets was 0.18 for alectinib vs. crizotinib and it was 0.14 for pts without brain metastases. These results indicate a preventive effect of alectinib against the (re-)occurrence of brain mets in patients with and without brain mets [93]. This is supported by the Japanese J-ALEX trial - also comparing alectinib to crizotinib - describing a HR for the time to progression of brain metastases or death for patients with CNS metastases at baseline with 0.16 (0.02-1.28). The hazard ratio for the development of brain metastases or death in patients without brain metastases at baseline was 0.41 (0.17-1.01) for alectinib as compared to crizotinib [85]. This, for the first time - since the introduction of prophylactic cranial irradiation in small-cell lung cancer - demonstrates a prophylactic effect for these patients by the administration of a systemic treatment.
Figure 1: (A) Proposed algorithm for the management of patients with ALK-positive NSCLC and brain metastases under treatment with 1L-ALKi. Postpone WBRT as long as possible. If BM not amenable for SRS switch to 2L-ALKi or if sparing WBI (2x20 Gy and/or hippocampal sparing) and TBP if later in the course of the disease. In case mechanism of resistance to 1L-ALKi is known, switch to appropriate 2L-ALKi if possible. BM brain metastases; SRS stereotactic radiotherapy; WBRT whole brain radiotherapy; TBP treatment beyond progression with 1L-ALK-Inhibitor; 1L-ALKi (alectinib, ceritinib, crizotinib) 2L-ALKi second line ALK-inhibitor (change to different ALK-inhibitor than 1L). (B) Proposed algorithm for the management of patients with ALK-positive NSCLC and brain metastases under treatment with crizotinib. Postpone WBRT as long as possible. If BM not amenable for SRS switch to 2nd generation ALKi or if sparing WBI (2x20 Gy and/or hippocampal sparing) and TBP if later in the course of the disease. BM brain metastases; SRS stereotactic radiotherapy; WBRT whole brain radiotherapy; TBP treatment beyond progression with crizotinib; 2nd ALKi second generation ALK-inhibitor.
Implications for the treatment of patients with ALK-positive NSCLC and brain metastases

Treating brain metastases represents an important challenge in the management of patients with ALK-positive NSCLC. ALK-inhibitor therapy results in high overall response rates and in long progression-free intervals. Yet, eventually, patients will progress, often due to secondary mutations or induction of other oncogenic drivers [90] and develop brain metastases. A considerable proportion of patients namely around 30% according recently published data [64] and baseline characteristics from clinical trials in 1st line treatment of ALK-positive NSCLC patients [86, 87, 27] already has a diagnosis of brain metastases before the start of ALK-inhibitor therapy. Registry data suggest that patients with brain metastases and ALK-positive NSCLC have a more favorable prognosis than patients whose tumors do not harbor an ALK-translocation. ALK-positive patients can be treated with several consecutive therapies. Thus, it is possible to effectively manage patients better over a considerably longer period of time. In the light of this, potential long-term side effects of radiotherapy become more important than they were when overall survival of patients was significantly shorter. The therapeutic strategy regarding brain metastases in ALK-positive NSCLC is already changing.

Indications for surgical interventions and stereotactic radiotherapy while postponing WBRT have become wider. WBRT can be planned sparing cerebral regions critical for neurocognitive functioning e.g. hippocampal-sparing whole-brain radiotherapy [72]. Given the high efficacy of ALK-inhibitors in brain metastases, modification of treatment algorithms by integration of systemic ALK-inhibitor therapy needs to be discussed. Postponing radiotherapy might defer potential long-term impairment by neurocognitive deficits to a later time point in the course of the disease. An early treatment of asymptomatic brain metastases could give patients a longer time without symptom impairment or radiotherapeutic interventions. The current recommendations against a general screening for brain metastases as part of the follow-up diagnostics for neurologically asymptomatic NSCLC patients should be discussed. It is fair to consider recommending regular MRI controls after defined intervals of 3-6 months at least for ALK-positive patients as already recommended for patients with advanced ALK-positive NSCLC by the German DGHO-Guideline for diagnosis and treatment of NSCLC. The same applies to the timely detection of further progression of brain metastases under ALK-inhibitor therapy. The goal should be to start radiotherapy in time and avoid potential risks of a delayed start as described for patients with EGFR-mutated lung cancer and respective treatment sequences [77].

Figure 1 shows a proposed algorithm for the management of patients with brain metastases after first-line ALK-inhibitor therapy. Patients with an isolated progression of brain metastases should receive stereotactic radiotherapy. Treatment with TKI should be either continued (treatment beyond progression) - a treatment approach supported by Ou et al. [28] or switched to another ALK-inhibitor (based on detection of resistance mechanism like second site mutation or the development of other oncogenic drivers [93]). If patients with isolated brain metastasis cannot undergo stereotactic radiotherapy, further treatment could be either local therapy or switching to an alternative systemic therapy. The latter has become a valid option over WBRT due to the availability of the second generation ALK-inhibitors ceritinib, alectinib (and brigatinib, as soon as approved or within compassionate use programs). This must be accompanied by close imaging and clinical monitoring. While this approach can clearly be recommended in case of asymptomatic metastases, it may also be an option for some patients with symptomatic metastases. In addition, the time of progression may influence the decision for systemic or local therapy of CNS metastases. Progression of brain metastases early in the course of the disease would then be an argument for switching to another ALK-inhibitor, since the potential neurocognitive side effects of radiotherapy might have a long-term impact on the patient’s quality of life. Switching to a second ALK-inhibitor therapy should also be recommended in case of CNS metastases not amenable to stereotactic radiotherapy and coexistence of extracerebral metastases. It needs to be pointed out that these recommendations can support clinical decision-making in this particularly challenging situation, keeping in mind that they are not based on the data from prospective studies.

ACKNOWLEDGMENTS

We would like to thank Roche Pharma AG for funding editorial support of a freelance medical writer.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

DISCLOSURES

Frank Griesinger:
Advisory Boards: Ariad, Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myer-Squibb, Celgene, Clovis, Lilly, Merck-Sharp-Dome, Novartis, Pfizer, Roche
Travel Support: Ariad, Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myer-Squibb, Celgene, Lilly, Merck-Sharp-Dome, Novartis, Pfizer, Roche
Scientific Support: Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myer-Squibb, Celgene, Lilly, Merck-Sharp-Dome, Novartis, Pfizer, Roche
Shares: none
Honoraria: Roche, Boehringer-Ingelheim.

Honoraria: Roche, Boehringer-Ingelheim.
REFERENCES

1. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiol Biomarkers Prev. 2016; 25: 16-27. https://doi.org/10.1158/1055-9965.EPI-15-0578.

2. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol. 2016; 893: 1-19. https://doi.org/10.1007/978-3-319-24223-1_1.

3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87-108. https://doi.org/10.3322/caac.21262.

4. Robert Koch Institut, Krebs in Deutschland 2011/2012, 10. Ausgabe 2015; online at http://www.krebsdaten.de/Krebs/DE/Content/Publicationen/Krebs_in_Deutschland/kid_2015/krebs_in_deutschland_2015.pdf?jsessionid=021D4590F465F9502B4E8D6E0584E6102_cid290?__blob=publicationFile, last accessed: 28.11.2016.

5. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, Niederle N, Stuschke M, Blum T, Deppermann KM, Ficker JH, Freitag L, Lübbe AS, et al. Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie. 2011; 65: 39-59. https://doi.org/10.1055/s-0030-1255961.

6. Griesinger F, Eberhardt W, Früh M, Gautschi O, Hilbe W, Hoffmann H, Huber RM, Pirker R, Poettgen C, Pritzkuleit R, Sebastian M, Thomas M, Ukena D, et al. DGHO Leitlinie Lungenkarzinom, nicht-kleinzelzig (NSCLC), Version April 2017, online at https://www.onkopedia.com/de/onkopedia/guidelines/lungenkarzinom-nicht-kleinzelzig-nsclc/@@view/html/index.html, Status April 2017, last accessed: 28.06.2017.

7. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-566. https://doi.org/10.1038/nature05945.

8. Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H, Kurashina K, Hatanaka H, Ueno T, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008; 68: 4971-76. https://doi.org/10.1158/0008-5427.

9. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008; 14: 4275-83. https://doi.org/10.1158/1078-0432.CCR-08-0168.

10. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008; 14: 6618-24. https://doi.org/10.1158/1078-0432.CCR-08-1018.

11. Takeuchi K, Choi YL, Togashi Y Soda M, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H. KIF5B-ALK, a novel fusion oncokine identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009; 15: 3143-49. https://doi.org/10.1158/1078-0432.CCR-08-3248.

12. Wong DW, Leung EL, So KK, Tam YY, Sihoo AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M; University of Hong Kong Lung Cancer Study Group. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Clin Cancer Res. 2009; 15: 1723-33. https://doi.org/10.1002/cncr.24181.

13. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131: 1190-203. https://doi.org/10.1016/j.cell.2007.11.025.

14. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-703. https://doi.org/10.1056/NEJMoai1006448.

15. Shinmura K, Kageyama S, Tao H, Bunai T, Suzuki M, Kato T, Takamochi K, Suzuki K, Tanahashi M, Niwa H, Ogawa H, Sugimura H. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
16. Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouaffik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016; 387: 1415-26. https://doi.org/10.1016/S0140-6736(16)00004-0.

17. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, Mino N, Iwakiri S, Sato K, Miyahara R, Okubo K, Manabe T, Date H. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010; 17: 889-97. https://doi.org/10.1245/s10434-009-0808-7.

18. Sakairi Y, Nakajima T, Yasufuku K, Ikebe D, Kageyama H, Soda M, Takeuchi H, Itami M, Iizasa T, Yoshino I, Mano H, Kimura H. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res. 2010; 16: 4938-45. https://doi.org/10.1158/1078-0432.CCR-10-0099.

19. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K, Soda M, Choi YL, Mano H, Ishikawa Y. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009; 22: 508-15. https://doi.org/10.1038/modpathol.2009.2.

20. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H, Ishikawa Y. EML4-ALK fusion gene is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008; 3: 13-17. https://doi.org/10.1097/JTO.0b013e31815b8b60.

21. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27: 4247-53. https://doi.org/10.1200/JCO.2009.22.6993.

22. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, Jheon S, Chung JH. Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer. Correlation with Fluorescence In Situ Hybridization. J Thorac Oncol. 2011; 6: 466-72. https://doi.org/10.1097/JTO.0b013e31820b8e28.

23. Bergethon K, Shaw AT, Ignatiu Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, et al. ROSI Rearrangements Define a Unique Molecular Class of Lung Cancers. J Clin Oncol. 2012; 25:1462-72. https://doi.org/10.1200/JCO.2011.35.6345.
34. Won YW, Joo J, Yun T, Lee GK, Han JY, Kim HT, Lee JS, Kim MS, Lee JM, Lee HS, Zo JL, Kim S. A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patients. Lung Cancer. 2015; 88: 201-207. https://doi.org/10.1016/j.lungcan.2015.02.006.

35. O'Dowd EL, Kumaran M, Anwar S, Palomo B, Baldwin DR. Brain metastases following radical surgical treatment of non-small cell lung cancer: is preoperative brain imaging important? Lung Cancer. 2014; 86: 185-89. https://doi.org/10.1016/j.lungcan.2014.08.021.

36. Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, Livingston RB, Gandara DR. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol. 2005; 23: 2955-61. https://doi.org/10.1200/JCO.2005.08.026.

37. Ji Z, Bi N, Wang J, Hui Z, Xiao Z, Feng Q, Zhou Z, Chen D, Lv J, Liang J, Fan C, Liu L, Wang L. Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. Int J Radiat Oncol Biol Phys. 2014; 89: 330-37. https://doi.org/10.1016/j.ijrobp.2014.02.025.

38. Li L. Clinical epidemiology of lung cancer in China: A retrospective study of 4205 patients. Eur Respir J. 2014; 58: 44.

39. Stanic K, Zwitzer M, Hitij NT, Kern I, Sadikov A, Cuer F. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol. 2014; 48: 173-83. https://doi.org/10.2478/raon-2014-0016.

40. Han G, Wei X, Wang X, Ying X, Guo X, Zhou X, Hu D, Zhen W. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: Is EGFR mutation associated with higher incidence of brain metastasis? Oncotarget. 2016; 7: 56998–57010. https://doi.org/10.18632/oncotarget.10933.

41. Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhmann EJ, Wong ET, Dahlberg SE, Huberman MS, DB. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015; 88: 108-11. https://doi.org/10.1016/j.lungcan.2015.01.020.

42. Kang HJ, Lim HJ, Park JS, Cho YJ, Yoon HI, Chung JH, Lee JH, Lee CT. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. Respir Med. 2014; 108: 388-94. https://doi.org/10.1016/j.resmed.2013.11.020.

43. Fallet V, Cadranel J, Double H, Topcr C, Monnet I, Chinet T, Olivero G, Foulon G, De Cremoux H, Vieira T, Antoine M, Wislez M. Prospective screening for ALK: clinical features and outcome according to ALK status. Eur J Cancer. 2014; 50: 1239-46. https://doi.org/10.1016/j.ejca.2014.02.001.

44. Guérin A, Sasame M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ. 2015; 18: 312-22. https://doi.org/10.3111/13696998.2014.1003644.

45. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, et al. First-line crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2014; 371: 2167-77. https://doi.org/10.1056/NEJMoa1408440.

46. Nokihara H, Hida T, Kondo M, Kim YJ, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshikoa H, Imamura F, Hotta K, Watanabe S, Goto K, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. J Clin Oncol. 2016; 34: 2016 (suppl; abstr 9008). https://doi.org/10.1200/JCO.2016.34.15_suppl.9008.

47. Kim DW, Mehra R, Tan DS, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase I trial. Lancet Oncol. 2016; 17: 452-63. https://doi.org/10.1016/S1470-2045(15)00614-2.

48. Felip E, Orlov S, Park K, Yu CJ, Tsai CM, Nishio M, Dols MC, McKeage M, Su MC, Mok TS, Scagliotti G, Spigel DR, Passos VQ, et al. Phase 2 study of ceritinib in ALK-naive patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM). Annals of Oncology. 2016; 27: 6. https://doi.org/10.1093/annonc/mdw383.03.

49. Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, Mok T, Spigel D, Felip E, Nishio M, Scagliotti G, Branle F, Emerenini C, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: Results from ASCEND-2. J Clin Oncol. 2016; 34: 2866-73. https://doi.org/10.1200/JCO.2015.65.5936.

50. Scagliotti G, Kim TM, Crinò L. Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): results from the confirmatory phase 3 ASCEND-5 study. Annals of Oncology.2016; 27: 6. https://doi.org/10.1093/annonc/mdw435.41.

51. Kim DW, Tiseo M, Ahn MJ, Reckamp K, Holmskov Hansen K, Kim SW, Huber R, West H, Groen H, Hochmair H, Leigh N, Gettinger S, Langer C, et al. Brontitib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial
(ALTA). J Clin Oncol. 2016; 34. https://doi.org/10.1200/JCO.2016.34.15_suppl.9007.

52. Kim SY, Kim JS, Park HS, Cho MJ, Kim JO, Kim JW, Song CJ, Lim SP, Jung SS. Screening of brain metastasis with limited Magnetic Resonance Imaging (MRI): Clinical Implications of using limited brain MRI during initial staging for non-small cell lung cancer patients. J Korean Med Sci. 2005; 20: 121-126. https://doi.org/10.3346/jkms.2005.20.1.121.

53. Duma N, Sanchez LJ, Miranda C, Glisch C, Abu-Ihweij K, Zhang S, Osorio C, Listo M, Harper HD, Gutierrez M. Prognostic factors for brain metastasis in non-small cell lung cancer (NSCLC): A single Institution’s experience for over 10 years. J Clin Oncol. 2015; 33. https://doi.org/10.1200/jco.2015.33.15_suppl.e19062.

54. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Leva MG, Kerr K, Popat S, Reck M, Senan S, Simo GV, Vansteenkiste J, Peters S. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27: v1-v27. https://doi.org/10.1093/annonc/mdw326.

55. Yoo H, Nam BH, Yang HS, Shin SH, Lee JS, Lee SH. Growth rates of metastatic brain tumors in non small cell lung cancer. Cancer. 2008; 113: 1043-47. https://doi.org/10.1002/cncr.23676.

56. Shaw MG, Ball DL. Treatment of brain metastases in lung cancer: strategies to avoid/reduce late complications of whole brain radiation therapy. Curr Treat Options Oncol. 2013; 14: 553-67. https://doi.org/10.1007/s11864-013-0258-0.

57. Aoyama H, Tago M, Kato N, Toyoda T, Kenjiyo M, Hirota S, Shioura H, Inomata T, Kunieda E, Hayakawa A, Aoyama H, Tago M, Kato N, Toyoda T, Kenjiyo M, Yoo N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295: 2483-91. https://doi.org/10.1001/jama.295.21.2483.

58. Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebnam J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerkaldi J, Siemers R, Carrie C, Gaspar LE, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004; 22: 157-65. https://doi.org/10.1200/JCO.2004.05.128.

59. Weestel V, Choma D, Clement F, Woronoff-Lemsi MC, Pugin JF, Dubiez A, Depierre A. Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg. 2000; 70: 1185–1190. https://doi.org/10.1016/S0003-4975(00)01731-8.

60. Gourcerol D, Scherpereel A, Debeugny S, Porte H, Cortot AB, Lafitte J. Relevance of an extensive follow-up after surgery for non-small cell lung cancer. Eur Respir J. 2013; 42: 1357-1364. https://doi.org/10.1183/09031936.00086712.

61. Jena A, Tanuja S, Talwar V, Sharma JB. Magnetic resonance (MR) patterns of brain metastasis in lung cancer patients: correlation of imaging findings with symptom. J Thorac Oncol. 2008; 3: 140-144. https://doi.org/10.1097/JTO.0b013e31816d775.

62. Sánchez de Cos J, Sojo González MA, Montero MV, Pérez Calvo MC, Vicente MJ, Valle MH. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer. 2009; 63: 140-145. https://doi.org/10.1016/j.lungcan.2008.04.013.

63. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012; 30: 419-425. https://doi.org/10.1200/JCO.2011.38.0527.

64. Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu J, Kavanagh BD, et al. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. J Clin Oncol. 2016; 34: 123-129. https://doi.org/10.1200/JCO.2015.62.0138.

65. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjiyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295: 2483-91. https://doi.org/10.1001/jama.295.21.2483.

66. Tsao MN, Lloyd N, Wong R, Chow E, Rakovitch E, Laperriere N. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev. 2006; 3: CD003869. https://doi.org/10.1002/14651858.CD003869.pub2.

67. Suh JH, Stea B, Nahid A, Kresl JJ, Fortin A, Mercier JP, Senzer N, Chang EL, Boyd AP, Cagnoni PJ, Shaw E. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol. 2006; 24: 106-114. https://doi.org/10.1200/JCO.2004.00.1768.

68. Chua D, Krzakowski M, Chouaid C, Pallotta MG, Martinez JJ, Gottfried M, Curran W, Throuvalas N. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: A single Institution's experience. J Thorac Oncol. 2010; 5: 1447-52. https://doi.org/10.1097/JTO.0b013e3181c44b9f.

69. Mulvonna PM, Nankivel MG, Barton R, Faivre-Finn C, Wilson P, Moore B, McColl E, Brisbane I, Ardzon A, Sydes B, Pugh C, Holt T, Bayman N, et al. Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall
sur vival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 8326061). J Clin Oncol. 2015; 33. https://doi.org/10.1200/jco.2015.33.15_suppl.8005.

70. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009; 10: 1037-1044. https://doi.org/10.1016/S1470-2045(09)70263-3.

71. Brown P, Asher AL, Ballman K, Farace E, Cerhan JH, Anderson KS, Carrero XM, Barker FG, Deming RL, Burri S, Menard C, Chung C, Stieber VW, et al. NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiotherapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J Clin Oncol. 2015; 33. https://doi.org/10.1200/jco.2015.33.18_suppl.lla4.

72. Gondi V, Pugh SL, Tome WA, Caine C, Corbin B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, Konski AA, Bauman GS, Shah S, et al. Preservation of memory with confo rmal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014; 32: 3810-3816. https://doi.org/10.1200/jco.2014.57.2909.

73. Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014; 74: 1023-1028. https://doi.org/10.1007/s00280-014-2578-6.

74. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014; 15: 1119-28. https://doi.org/10.1016/S1470-2045(14)70362-6.

75. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltsshire R, et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol. 2015; 33: 1881-1888. https://doi.org/10.1200/jco.2014.59.0539.

76. Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JCH, Dingenmans A, Kim DW, de Marinis F, Schultz M, Liu S, Fish S, Koth A, Ou SHI. Cumulative incidence rates for CNS and non-CNS progression by baseline CNS metastases status using data from two alectinib phase II studies. J Clin Oncol. 2016; 34. https://doi.org/10.1200/jco.2016.34.15_suppl.9063.

77. Magnuson J, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL. Impact of deferring Radiation Therapy in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who develop brain metastases. Int J Radiat Oncol Biol Phys. 2016; 95: 673-679. https://doi.org/10.1016/j.ijrob.2016.01.037.

78. Alsan Cetin I, Akgun Z, Abacioglu U. Who may benefit from prophylactic cranial irradiation amongst stage III non-small cell lung cancer patients? J BUON. 2013; 18: 453-458.

79. Boggs DH, Robbins HI, Langer CJ, Traaynor AM, Berkowitz MJ, Mehta MP. Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation. Clin Lung Cancer. 2014; 15: 433-440. https://doi.org/10.1016/j.clcancer.2014.06.008.

80. Arrieta O, Saavedra-Perez D, Kuri R, Aviles Salas A, Martinez L, Mendoza-Posada D, Castillo P, Astorga A, Guzman E, De la Garza J. Brain metastases development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: A prospective analysis. BMC Cancer. 2009; 9:119. https://doi.org/10.1186/1471-2407-9-119.

81. Hendriks LEL, Smit EF, Vosse BA, Mellem WW, Heideman DA, Bootma GP, Westenend M, Pitz C, de Vries GJ, Houben R, Grünberg K, Bendek M, Specel EJ, Dingemans AM. EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases? Lung Cancer. 2014; 84: 86-91. https://doi.org/10.1016/j.lungcan.2014.01.006.

82. American Cancer Society available at https://www.cancer.org/: accessed June 26th 2017.

83. Robinson LA, Ruckdeschel J, Wagner H e Stevens C, American College of Chest Physicians. Diagnosis and Management of Lung Cancer; ACCP Guidelines 2nd Edition, Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines 2nd edition. Chest. 2007; 132:243S-265S. https://doi.org/10.1378/chest.07-1379.

84. Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev. 2014; 40: 300-6. https://doi.org/10.1016/j.ctrv.2013.07.002.

85. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label randomized phase 3 trial. Lancet. 2017; 390: 29-39. https://doi.org/10.1016/S0140-6736(17)30565-2.

86. Peters S, Camidge R, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Péro M, Dziadziuszko R, Rosell R, Zeature A, Mitry E, Golding S, et al. Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer. N
87. Soria JC, Tan D, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017; 389: 917-929. https://doi.org/10.1016/S0140-6736(17)30123-X.

88. Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol. 2017; 18: 874-886. https://doi.org/10.1016/S1470-2045(17)30339-X.

89. Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CI, et al. Brigatinib in patients with Crizotinib-refractory anaplastic lymphoma kinase–positive Non–Small-Cell Lung Cancer: A randomized, multicenter phase II trial. J Clin Oncol. 2017; 35: 2490-2498. https://doi.org/10.1200/JCO.2016.71.5904.

90. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012; 18:1472-82. https://doi.org/10.1158/1078-0432.CCR-11-2906.

91. Barlesi F, Dingemans AM, Yang JCH, Ou SI, Ahn JS, De Petris L, Hughes B, Lena H, Bordogna W, Golding S, Morcos PN, Balas B, Zeaiter A, et al. Updated efficacy and safety from the global phase-II study NP28763 of alectinib in patients with previously treated ALK+ non-small-cell lung cancer (NSCLC) 2016, Poster 1263p. Annals of Oncology. 2016; 27: 416-454. https://doi.org/10.1093/annonc/mdw383.63.

92. Novello S, Mazieres J, Oh JJ, de Castro J, Migliorino MR, Helland A, Dziadziszko R, Griesinger F, Kob F, Zeaiter A, Cardona A, Balas B, Johannsdottir E, et al. Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC). Annals of Oncology. 2017; 28: v605-v649. https://doi.org/10.1093/annonc/mdy121.

93. Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SHI, Pérol M, Dziadziszko R, Ahn JS, Rosell R, Zeaiter A, Mitry E, Nueesch E, et al. Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study. Annals of Oncology. 2017; 28. https://doi.org/10.1093/annonc/mdx440.057.

94. Liu J, Kong L, Meng X, Yue J, Sun X, Yu J. Development of brain metastases in stage III/IV non-small cell lung cancer patients treated with or without erlotinib. J Clin Oncol. 2013; 31:e19011. https://10.0.4.176/jco.2013.31.15_suppl.e19011.